



NEWS — 12 MARCH 2014

Novimmune appoints Andrew J. Oakley as CFO

GENEVA — Novimmune SA announced today that Andrew J. Oakley has joined the company as Chief Financial Officer.

Andrew Oakley, an Australian national, who most recently served as the CFO of Swiss-based Actelion Ltd, is also joining Novimmune's Executive Committee. His appointment is effective immediately.

In announcing the appointment, Jack Barbut, Chief Executive Officer of Novimmune, commented, "I am very pleased to welcome Andrew to Novimmune. With Novimmune's research and development efforts maturing, our company will benefit significantly from his extensive experience in both the biopharmaceutical industry and the global capital markets."

Dr. Eduard Holdener, Chairman of Novimmune, added, "We are delighted that Novimmune has been able to attract a professional of such high caliber as Andrew. The appointment of such an experienced public company CFO highlights our ambition to rapidly advance Novimmune's corporate and business strategy."

In his ten years at Actelion, a global biopharmaceutical company with a market capitalization exceeding CHF 10 billion, Andrew built and led a global finance function and initiated and executed a number of Capital Markets Transactions. Prior to this appointment, Andrew held a number of senior managerial and financial roles at several organizations in Australia, the UK and the US.

Andrew J. Oakley said, "I am excited to join my new colleagues at Novimmune at this important time in the company's development. I am confident that together, we will continue to create value for our investors, and benefits for patients, by advancing important new medicines either through strategic collaborations or, in the case of orphan indications, on our own."

[About Novimmune](#)

Novimmune SA is a privately-held drug discovery and development company focused on the creation of antibody-based drugs to treat patients with inflammatory diseases, autoimmune disorders, and cancer. To date, the company has a pipeline that consists of a balance of preclinical and clinical candidates for validated and novel targets. In addition, Novimmune has created a proprietary, next-generation drug discovery platform that includes the ability to generate unique and proprietary bi-specific antibodies.

The company also plans to soon bring targeted medicines to market for selected orphan drug applications.

For further information contact:

Jack Barbut, CEO

Novimmune SA

14 Chemin des Aulx

1228 Plan-les-Ouates, Geneva

Switzerland

Tel: +41 22 839 71 41

Fax: +41 22 839 71 43